Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H28ClN3O4 |
Molecular Weight | 397.896 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCOC(=O)CN1CCC(CC1)NC(=O)C2=CC(Cl)=C(N)C=C2OC
InChI
InChIKey=AQMLPMSSCWTNNN-UHFFFAOYSA-N
InChI=1S/C19H28ClN3O4/c1-3-4-9-27-18(24)12-23-7-5-13(6-8-23)22-19(25)14-10-15(20)16(21)11-17(14)26-2/h10-11,13H,3-9,12,21H2,1-2H3,(H,22,25)
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. | 2000 Apr 25 |
|
Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors in prefrontal cortical pyramidal neurons by a novel allosteric potentiator. | 2001 Jul |
|
Potentiation of responses to AMPA on central neurones by LY392098 and LY404187 in vivo. | 2001 Jun |
|
Novel AMPA receptor potentiators LY392098 and LY404187: effects on recombinant human AMPA receptors in vitro. | 2001 Jun |
|
Mechanism and impact of allosteric AMPA receptor modulation by the ampakine CX546. | 2001 Nov |
|
Therapeutic approaches to age-associated neurocognitive disorders. | 2001 Sep |
|
Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model. | 2002 Apr 5 |
|
Randomized, double-blind, placebo-controlled international clinical trial of the Ampakine CX516 in elderly participants with mild cognitive impairment: a progress report. | 2002 Aug-Oct |
|
CX-516 Cortex pharmaceuticals. | 2002 Jul |
|
Positive modulators of AMPA receptors as a potential treatment for schizophrenia. | 2002 Jul |
|
Survival signaling and selective neuroprotection through glutamatergic transmission. | 2002 Mar |
|
Cortex Pharmaceuticals, Inc. Maintaining brain function goes a long way. | 2003 Nov |
|
Modulation of AMPA receptor kinetics differentially influences synaptic plasticity in the hippocampus. | 2004 |
|
Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. | 2005 Apr |
|
Glutamate-based therapeutic approaches: ampakines. | 2006 Feb |
|
Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. | 2006 Oct |
|
Ampakine CX516 ameliorates functional deficits in AMPA receptors in a hippocampal slice model of protein accumulation. | 2008 Nov |
|
Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting. | 2009 Nov |
|
Systematic review of pharmacological treatments in fragile X syndrome. | 2009 Oct 13 |
|
Glutamatergic targets for enhancing extinction learning in drug addiction. | 2010 Dec |
|
Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats. | 2010 Feb 11 |
Patents
Name | Type | Language | ||
---|---|---|---|---|
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
287399-47-7
Created by
admin on Sat Dec 16 11:14:58 GMT 2023 , Edited by admin on Sat Dec 16 11:14:58 GMT 2023
|
PRIMARY | |||
|
XVR3JT7PGA
Created by
admin on Sat Dec 16 11:14:58 GMT 2023 , Edited by admin on Sat Dec 16 11:14:58 GMT 2023
|
PRIMARY | |||
|
9822171
Created by
admin on Sat Dec 16 11:14:58 GMT 2023 , Edited by admin on Sat Dec 16 11:14:58 GMT 2023
|
PRIMARY |
ACTIVE MOIETY